On its way to becoming the world’s biggest seller of generic medicines, Teva Pharmaceutical Industries Ltd. was known for its fierce efforts to end patent protection for brand-name drugs. But now the Israeli drug maker is pulling out all the stops to protect one of its own brand-name drugs from such a reckoning.. Today, the U.S. Supreme Court .  of an appeals court decision that could have paved the way for generic versions of multiple-sclerosis drug Copaxone.. Even though it’s a brand-name medicine at a largely generic drug maker, Copaxone is one of Teva’s most important products. Last year, Copaxone rung up $4.3 billion of the company’s $20.3 billion in total revenues. And analysts figure it accounts for 40% or more of Teva’s profit.. More on this after the jump…